REGENXBIO/$RGNX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About REGENXBIO
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
Ticker
$RGNX
Sector
Primary listing
Employees
353
Headquarters
Website
REGENXBIO Metrics
BasicAdvanced
$586M
-
-$3.43
1.11
-
Price and volume
Market cap
$586M
Beta
1.11
52-week high
$13.93
52-week low
$5.04
Average daily volume
619K
Financial strength
Current ratio
3.127
Quick ratio
2.873
Long term debt to equity
104.521
Total debt to equity
127.149
Interest coverage (TTM)
-5.52%
Profitability
EBITDA (TTM)
-148.753
Gross margin (TTM)
82.44%
Net profit margin (TTM)
-112.70%
Operating margin (TTM)
-105.66%
Revenue per employee (TTM)
$440,000
Management effectiveness
Return on assets (TTM)
-17.88%
Return on equity (TTM)
-62.49%
Valuation
Price to revenue (TTM)
3.811
Price to book
2.74
Price to tangible book (TTM)
2.74
Price to free cash flow (TTM)
-6.545
Free cash flow yield (TTM)
-15.28%
Free cash flow per share (TTM)
-1.774
Growth
Revenue change (TTM)
74.95%
Earnings per share change (TTM)
-34.39%
3-year revenue growth (CAGR)
-31.48%
10-year revenue growth (CAGR)
45.59%
3-year earnings per share growth (CAGR)
18.86%
10-year earnings per share growth (CAGR)
-5.31%
What the Analysts think about REGENXBIO
Analyst ratings (Buy, Hold, Sell) for REGENXBIO stock.
Bulls say / Bears say
REGENXBIO has accelerated enrollment in its RGX-202 AFFINITY DUCHENNE pivotal trial, which is expected to finish by October 2025, setting up the therapy for a mid-2026 BLA submission (Reuters).
Despite a decrease in Zolgensma royalties, Q2 2025 revenues were partly supported by $2.7 million in service revenue from the Nippon Shinyaku partnership, showing improved revenue diversification (Reuters).
REGENXBIO ended Q2 2025 with a projected cash runway extending into early 2027, giving the company financial stability for key clinical readouts and commercialization preparations (Reuters).
The FDA extended the PDUFA date for RGX-121 from November 9, 2025 to February 8, 2026, delaying potential approval and increasing regulatory uncertainty (Reuters).
Regenxbio’s stock is down nearly 30% over the past 12 months, indicating declining investor confidence in gene therapy after several industry setbacks (Barron's).
In Q2 2025, net loss widened to $70.9 million from $53.0 million a year earlier, while revenue fell to $21.4 million, highlighting continued cash burn and declining royalty income (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2025.
REGENXBIO Financial Performance
Revenues and expenses
REGENXBIO Earnings Performance
Company profitability
REGENXBIO News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for REGENXBIO stock?
REGENXBIO (RGNX) has a market cap of $586M as of November 06, 2025.
What is the P/E ratio for REGENXBIO stock?
The price to earnings (P/E) ratio for REGENXBIO (RGNX) stock is 0 as of November 06, 2025.
Does REGENXBIO stock pay dividends?
No, REGENXBIO (RGNX) stock does not pay dividends to its shareholders as of November 06, 2025.
When is the next REGENXBIO dividend payment date?
REGENXBIO (RGNX) stock does not pay dividends to its shareholders.
What is the beta indicator for REGENXBIO?
REGENXBIO (RGNX) has a beta rating of 1.11. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.